MNTS
AI MemoMomentus
As of 2026-10-17/Confidence medium/Horizon 6‑12m
Data freshness
AI Memo
As of 2026-10-17 • Model: RankAlpha Sentiment Codex
Decision Panel
Action, confidence, horizon, and decision blockers at a glance.
Action
—
Confidence
medium
Horizon
6‑12m
Key catalyst
ARCSPACE contract adds a Vigoride-9 payload • 2026-10-15
Base target: $2 / p=50% prob
Biggest risk
Revenue remains highly uneven: second-quarter service revenue was $25,000, while first-half operating cash use was $14.9 million. Financing strengthened cash but diluted shareholders, and the ATM remained available as of the August filing. New contract values and a NASA follow-on award are unconfirmed. [#10-Q-2026-08-11] SEC 10-Q
Invalidation
Break below $1 or thesis failure.
What would change my mind?
The October commercial contract, September Vigoride-7 demonstration and NASA formulation task order show customer and technical progress. Sustained contract conversion and successful 2027 missions could improve confidence. [#PR-2026-10-15] Company ARCSPACE release Company Vigoride-7 release
Research note
Recommendation
—
Confidence
medium
As of
2026-10-17
Base target
$2
p=50%
Bull target
$4
p=20%
Bear target
$1
p=30%
Key bullets
Fast scan of bull, bear, and watch items
BullKey bullets
- Test of the 2026 revenue forecast and dilution risk
- Execution of planned 2027 Vigoride missions
- The October commercial contract, September Vigoride-7 demonstration and NASA formulation task order show customer and technical progress.
BearKey bullets
- Operating cash use, ATM issuance and potential further dilution may offset contract progress.
- [#10-Q-2026-08-11] SEC 10-Q
- The $10 million 2026 revenue forecast requires substantial second-half recognition after $3.24 million in the first half; milestone timing may shift.
WatchKey bullets
- ARCSPACE contract adds a Vigoride-9 payload
Summary
High-level snapshot
Recommendation
-
Model confidence
medium
Timeframe
6‑12m
Asset
Equity
Trigger
-
Base case: $2 (p=50%)
Target spread vs base: +60% / -51%
Scenario probabilities
Bull Target: $4 (p=20%)Base Target: $2 (p=50%)Bear Target: $1 (p=30%)
Commentary
Recent company announcements are constructive, especially the October 15 commercial contract, but its economics are undisclosed. No verified post-announcement price reaction, current analyst revisions, options skew, short-interest measure or sufficiently covered social signal was available; numerical zero fields above denote unavailable data, not measured neutrality. Maintain a cautious monitoring view despite the stronger cash balance.
As of 2026-10-17 • Updated bi-weekly / post-earningsSource: Internal modelMethodology
Analyst Summary
Thesis highlights from the latest analysis
Bull Case
The October commercial contract, September Vigoride-7 demonstration and NASA formulation task order show customer and technical progress. Sustained contract conversion and successful 2027 missions could improve confidence. [#PR-2026-10-15] Company ARCSPACE release Company Vigoride-7 release
Bear Case
Revenue remains highly uneven: second-quarter service revenue was $25,000, while first-half operating cash use was $14.9 million. Financing strengthened cash but diluted shareholders, and the ATM remained available as of the August filing. New contract values and a NASA follow-on award are unconfirmed. [#10-Q-2026-08-11] SEC 10-Q
Drivers
Scannable catalysts and supporting factors
- Test of the 2026 revenue forecast and dilution risk
- Execution of planned 2027 Vigoride missions
Scenarios
Bull Target (Scenario probability)
$4 / p=20% prob
Base Target (Scenario probability)
$2 / p=50% prob
Bear Target (Scenario probability)
$1 / p=30% prob
Analysis 2026-10-17 · RankAlpha Sentiment Codex
Analysis reference price unavailable. Targets are shown without scenario returns.
Sentiment & Exposure
News Sentiment (30d)
0.20
Social Sentiment (7d)
0.00
Events
Other notable items detected
- EVENT2026-10-15ARCSPACE contract adds a Vigoride-9 payloadMomentus announced an ARCSPACE hosted-payload contract on October 15 for an autonomous welding demonstration aboard Vigoride-9, projected to launch in 2027. Contract value was not disclosed, so the award does not establish a revenue inflection. [#PR-2026-10-15] Company releaseProb 100.00% • Move 5.00% • Priced-in 75.00%
- EVENT2027-12-31Potential NASA FALCON-Lidar follow-on decisionNASA awarded Momentus a task order for the competitive formulation phase. NASA may subsequently decide whether to award a satellite build-and-flight contract; neither a follow-on award nor its value is established. The date is an analyst monitoring horizon, not company guidance. [#PR-2026-09-24] Company releaseProb 35.00% • Move 12.00% • Priced-in 25.00%
Short-term Catalysts
Next few weeks
- Test of the 2026 revenue forecast and dilution risk2026-12-31Momentus forecast $10 million of 2026 revenue in May, versus $3.24 million recognized in the first half and just $25,000 in the second quarter. The June 30 filing reported $107.6 million of cash, $14.9 million of first-half operating cash use, and subsequent ATM sales; it said up to $58 million remained available under that ATM as of the filing. The August termination of an unused $50 million equity-purchase facility did not terminate the separate ATM. Year-end is a monitoring horizon, not an announced results date. [#10-Q-2026-08-11] [#8-K-2026-08-25] Company shareholder-letter release SEC 10-Q SEC 8-KProb 70% • Move -15% • Priced-in 55%
Long-term Catalysts
Months to a year
- Execution of planned 2027 Vigoride missions2027-12-31The June 10-Q said Vigoride-8 was planned for 2027 with two NASA payloads. The new ARCSPACE payload is slated for Vigoride-9, also projected for 2027. Launch and mission execution could validate the platform, but timing, economics and further awards remain uncertain. [#10-Q-2026-08-11] [#PR-2026-10-15] SEC 10-Q Company releaseProb 55% • Move 15% • Priced-in 30%
Risks
- Operating cash use, ATM issuance and potential further dilution may offset contract progress. [#10-Q-2026-08-11] SEC 10-Q
- The $10 million 2026 revenue forecast requires substantial second-half recognition after $3.24 million in the first half; milestone timing may shift. [#10-Q-2026-08-11] Company shareholder-letter release
- The ARCSPACE contract has no disclosed value, the NASA FALCON-Lidar follow-on is not awarded, and planned 2027 launches carry execution risk. Company ARCSPACE release Company NASA release
Peers
| Symbol | Summary |
|---|---|
| LUNR | Adjacent space-infrastructure comparison with a different mission mix and scale; not a direct valuation multiple. Intuitive Machines IR |
| RKLB | Adjacent spacecraft and space-services operating comparison, but substantially different in scale; not a direct MNTS valuation multiple. Rocket Lab IR |
Sources
Internal and external references used in this analysis
- Model source: RankAlpha Sentiment Codex
- Analysis date: 2026-10-17

